# Entirety Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/entirety-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Michigan City, US
- Website: www.entiretybio.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Feb 11, 2026)
- Investors on record: 6

## About

Based in Indiana, US and founded in 2022 by Jake Edick (CEO), and Carolyn Worlding, Entirety Biomedical is focused on creating advanced medical solutions. In February 2026, Entirety Biomedical raised USD 1.2 million in seed funding led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage Capital, Revere Partners, Mass Medical Angels, Community Equity Partners, and American Society of Plastic Surgeons. 
Entirety Biomedical's primary offering is its Curasorb Alloy technology, a novel line of absorbable metal implants designed to enhance surgical treatment options and improve patient recovery outcomes. These implants match the reliability and ease of traditional titanium implants but safely absorb once healing is complete, addressing long-term complications and costs associated with permanent implants. Curasorb implants are relevant in cosmetic, trauma, and reconstruction procedures, serving hospitals, surgical centers, and healthcare providers across North America and Europe.
Entirety Biomedical generates revenue primarily through direct sales of its Curasorb absorbable implants to healthcare facilities, including hospitals and outpatient surgical centers. Their business model focuses on B2B transactions, negotiating contracts with medical providers who utilize their products in various surgical procedures. Revenue is recognized at the point of sale when healthcare providers purchase the implants for surgeries, with the Curasorb product being integral to their revenue stream. Specific pricing information and transaction volumes are not publicly disclosed, consistent with industry practices.
The company plans to use the February 2026 funding to advance testing of its absorbable implants and prepare for initial clinical studies.

## Funding rounds

- Seed, Feb 11, 2026, $1.2M — Mass Medical Angels, Revere Partners, Michigan Rise, NuFund Venture Group, Union Heritage Capital, Community Equity Partners

## Investors

- Mass Medical Angels — Seed
- Revere Partners (https://capitalatlas.ai/funds/revere-partners) — Seed
- Michigan Rise (https://capitalatlas.ai/funds/michigan-rise) — Seed
- NuFund Venture Group (https://capitalatlas.ai/funds/nufund-venture-group) — Seed
- Union Heritage Capital — Seed
- Community Equity Partners — Seed